A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease
Summary
- Eligibility
- for people ages 60-85 (full criteria)
- Location
- at San Francisco, California and other locations
- Dates
- study startedestimated completion
- Principal Investigator
- by Lawren VandeVrede
Description
Summary
Official Title
Keywords
Eligibility
Locations
Lead Scientist at UCSF
- Lawren VandeVrede
Dr. Lawren VandeVrede is a neurologist who cares for patients with dementia and other memory disorders. VandeVrede's research focuses on improving scientific understanding of neurodegenerative disorders (conditions in which nerve cells progressively deteriorate or die) and developing treatments for them.
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Biogen
- ID
- NCT05310071
- Phase
- Phase 3 Alzheimer's Disease Research Study
- Study Type
- Interventional
- Participants
- Expecting 1512 study participants
- Last Updated